Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results

Yoshinosuke Fukuchi, Ronnie Samoro, Rustem Fassakhov, Hiroyuki Taniguchi, Jan Ekelund, Lars Goran Carlsson, Masakazu Ichinose

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Background and objective The efficacy and tolerability of budesonide/formoterol versus formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD) was evaluated. Methods In this randomized, double-blind, parallel-group, phase III study (NCT01069289), patients with moderate to severe COPD for ≥2 years received either budesonide/formoterol 160/4.5 μg two inhalations twice daily via Turbuhaler® or formoterol 4.5 μg two inhalations twice daily via Turbuhaler® for 12 weeks. Salbutamol was available as reliever medication. Primary outcome variable: change from baseline to average during treatment in pre-dose forced expiratory volume in 1 s (FEV1). Results One thousand two hundred ninety-three patients were randomized (budesonide/formoterol n = 636; formoterol n = 657). Both budesonide/formoterol and formoterol increased pre-dose FEV1 versus baseline (improvements of 4.6% and 1.5% over baseline, respectively), with the increase from baseline being significantly greater with budesonide/formoterol versus formoterol (budesonide/formoterol: formoterol ratio 1.032; 95% confidence interval: 1.013-1.052; P = 0.0011). The budesonide/formoterol group had a significantly prolonged time to first exacerbation versus the formoterol group (hazard ratio: 0.679; 95% confidence interval: 0.507-0.909; P = 0.0094) and significantly greater improvements in many secondary outcome measures. Both treatments were well tolerated; the incidence and type of adverse events were similar: most commonly reported (budesonide/formoterol vs formoterol): COPD (8.0% vs 9.4%) and nasopharyngitis (5.5% vs 4.9%). Conclusions Budesonide/formoterol 160/4.5 μg two inhalations twice daily was effective and well tolerated in patients with moderate to severe COPD, offering benefits over formoterol alone in terms of improved lung function and reduced risk of exacerbation. These results confirm that budesonide/formoterol is effective and well tolerated in adults with moderate to severe COPD and that it offers benefits over formoterol alone, particularly in terms of improved lung function and a reduction in the risk of exacerbation.

Original languageEnglish
Pages (from-to)866-873
Number of pages8
JournalRespirology
Volume18
Issue number5
DOIs
Publication statusPublished - 2013 Jul

Keywords

  • budesonide/formoterol
  • chronic obstructive pulmonary disease
  • exacerbation
  • formoterol
  • lung function

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results'. Together they form a unique fingerprint.

Cite this